- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00448838
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells.
PURPOSE: This clinical trial is studying how well giving cetuximab together with gemcitabine and oxaliplatin works in treating patients with locally advanced or metastatic pancreatic cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Determine the progression-free survival of patients with locally advanced or metastatic pancreatic cancer treated with cetuximab, gemcitabine hydrochloride, and oxaliplatin.
Secondary
- Determine the complete response and partial response in patients treated with this regimen.
- Determine the time to progression in patients treated with this regimen.
- Determine the duration of response in patients treated with this regimen.
- Determine the survival of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a nonrandomized, open-label, pilot study.
Patients receive cetuximab IV over 1-2 hours on days 1 and 8, gemcitabine hydrochloride IV over 100 minutes on day 1, and oxaliplatin IV over 2-4 hours on day 2. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Florida
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Sylvester Comprehensive Cancer Center - Miami
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed pancreatic cancer
- Locally advanced or metastatic disease
No active CNS metastases
- Patients with stable CNS disease, who have undergone radiotherapy within the past 4 weeks and who have been on a stable dose of corticosteroids for > 3 weeks, are eligible
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 mg/dL
- Alkaline phosphatase ≤ 3 times upper limit of normal (ULN) (5 times ULN if known hepatic metastases)
- AST and ALT ≤ 3 times ULN (5 times ULN if known hepatic metastases)
- Creatinine ≤ 1.5 mg/dL
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 90 days after completion of study treatment
No significant history of uncontrolled cardiac disease, including any of the following:
- Uncontrolled hypertension
- Unstable angina
- Myocardial infarction within the past 6 months
- Uncontrolled congestive heart failure
- Cardiomyopathy with decreased ejection fraction
- No prior severe infusion reaction to a monoclonal antibody
- No active infection or fever ≥ 38.5°C within the past 3 days
- No known hypersensitivity to any components of gemcitabine hydrochloride, oxaliplatin, or to a monoclonal antibody
- No peripheral neuropathy ≥ grade 2
- No known HIV positivity
- No hepatitis B or C infection (active, previously treated, or both)
- No other medical condition, including mental illness or substance abuse, that would preclude study compliance
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from all prior therapy, including surgery
- More than 30 days since prior investigational therapy
- More than 4 weeks since prior radiotherapy
- No prior radiotherapy to more than 25% of bone marrow
- More than 30 days since prior chemotherapy
- No prior chemotherapy for metastatic pancreatic cancer
- Prior fluoropyrimidine as a radiosensitizer allowed
- Prior gemcitabine hydrochloride in the adjuvant setting allowed
- No prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway
- No prior allogeneic transplantation
- No other concurrent investigational therapy, chemotherapy, or systemic antineoplastic therapy
- No other concurrent treatment that targets the EGFR
- No other concurrent monoclonal antibody therapy
- No concurrent radiotherapy except for local control of bone pain
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-free survival
Tijdsspanne: The cumulative percentage of intent to treat patients who experience disease progression at 1, 2, 3, 4, 5, and 6 months will be characterized with corresponding 95% confidence intervals
|
The corresponding progression-free survival curve and cumulative risk of progression as a function of time post treatment initiation will be estimated using the Kaplan-Meier method
|
The cumulative percentage of intent to treat patients who experience disease progression at 1, 2, 3, 4, 5, and 6 months will be characterized with corresponding 95% confidence intervals
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Toxicity
Tijdsspanne: Frequency and severity of adverse events according to the NCI CTCAE V 3.0 body system and severity criteria will be described.
|
Frequency and severity of adverse events according to the NCI CTCAE V 3.0 body system and severity criteria will be described.
|
|
Response rate (complete response and partial response)
Tijdsspanne: After every 4th cycle; End of Treatment and Follow-up
|
The response rate will be determined by the RECIST criteria.
After every 4th cycle; End of Treatment and Follow-up
|
After every 4th cycle; End of Treatment and Follow-up
|
Duration of response
Tijdsspanne: The time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented
|
the time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started
|
The time measurement criteria are met for CR or PR (whichever status is recorded first) until the first date that recurrence or PD is objectively documented
|
Overall survival
Tijdsspanne: Overall survival will also be estimated using the product-limit method of Kaplan-Meier.
|
Overall survival will also be estimated using the product-limit method of Kaplan-Meier.
|
Overall survival will also be estimated using the product-limit method of Kaplan-Meier.
|
Time to progression
Tijdsspanne: The time from the start of the treatment until the criteria for disease progression are met
|
The time from the start of the treatment until the criteria for disease progression are met, taking as reference the smallest measurements recorded since the treatment started (also referred to in the RECIST criteria as duration of stable disease).
|
The time from the start of the treatment until the criteria for disease progression are met
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Neoplasmata
- Neoplasmata per site
- Endocriene systeemziekten
- Neoplasmata van het spijsverteringsstelsel
- Endocriene klierneoplasmata
- Alvleesklier Ziekten
- Pancreasneoplasmata
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Antineoplastische middelen, immunologisch
- Gemcitabine
- Oxaliplatine
- Cetuximab
Andere studie-ID-nummers
- 20057548
- SCCC-2005141 (Andere identificatie: University of Miami Sylvester Comprehensive Cancer Center)
- WIRB-20052717 (Andere identificatie: Western Insitutional Review Board)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Alvleesklierkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Andrei IagaruNiet meer beschikbaarCarcinoïde tumoren | Eilandcel (Pancreatic NET) | Andere neuro-endocriene tumorenVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterWervingHoofd-hals plaveiselcelcarcinoom | Marge beoordelingNederland
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenBeëindigdGemetastaseerde colorectale kankerNederland
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityWervingColo-rectale kanker | Capecitabine | CetuximabChina
-
Eben RosenthalNational Cancer Institute (NCI)BeëindigdPancreas AdenocarcinoomVerenigde Staten
-
HiberCell, Inc.BeëindigdColorectale kankerVerenigde Staten, Puerto Rico, Duitsland, Frankrijk
-
Merck KGaA, Darmstadt, GermanyVoltooidEerder onbehandelde gemetastaseerde colorectale kankerFrankrijk, Italië, Polen, Duitsland, Hongkong, Oostenrijk, Brazilië, Israël, Griekenland, Argentinië, Thailand, België, Australië, Mexico
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCVoltooidGemetastaseerde colorectale kankerOostenrijk
-
Cancer Institute and Hospital, Chinese Academy...Werving
-
Poitiers University HospitalVoltooidUitgezaaide darmkankerFrankrijk
-
Copenhagen University Hospital at HerlevOnbekend